| Factor Information | |
|---|---|
| Data ID | 1749 |
| Factor | incidence of TA receiving intervention |
| Description | Compared with controls, subjects in the dexmedetomidine group had significantly fewer tachyarrhythmias (29% versus 38%; P<0.001), tachyarrhythmias receiving intervention (14% versus 23%; P<0.001), bradyarrhythmias (18% versus 22%; P=0.03), and bradyarrhythmias receiving intervention (12% versus 16%; P=0.04). |
| Biomarker | NA |
| Classification | A3 (clinical factor - disease & symptom) |
| Association | |
|---|---|
| Application | treatment and prognosis |
| Objective | examine for an association between dexmedetomidine use in the immediate postoperative period and subsequent arrhythmia development after heart surgery |
| p Value | <0.001 |
| Conclusion | Compared with controls, subjects in the dexmedetomidine group had significantly fewer tachyarrhythmiasversus, bradyarrhythmias, and bradyarrhythmias receiving intervention. |
| Risk Factor | protective factor |
| CHD Type | |
|---|---|
| ID | 148 |
| CHD Type | NA |
| CHD Subtype | NA |
| Reference | |
|---|---|
| PMID | 25878324 |
| Year | 2015 |
| Title | Association between perioperative dexmedetomidine and arrhythmias after surgery for congenital heart disease. |
| Sample | ||
|---|---|---|
| Population | children | |
| Source | an ongoing prospective observational study | |
| Region | Nashville, USA | |
| Method | prospective observational study | |
| Race | North America | |
| Disease History | N/A | |
| Treatment History | cardiac surgery | |
| Group | DEX(dexmedetomidine) group(Treatment) | CHD group without DEX(Control) |
| Number | 65 | 261 |
| Age | 784 (175 to 1794) days | 127 (13 to 379) days |
| Gender (Male: Female) | N/A | N/A |
| Marker Level | 14% (65) | 23% (261) |
